BlackRock Group’s Ultragenyx Pharmaceutical RARE Stock Holding History

BlackRock Group’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$1.78M	Buy	25,325 +1,719	+7%	+$122K	﹤0.01%	1845
2016 Q3	$1.67M	Buy	23,606 +676	+3%	+$43.1K	﹤0.01%	1741
2016 Q2	$1.12M	Buy	22,930 +3,150	+16%	+$204K	﹤0.01%	1913
2016 Q1	$1.25M	Sell	19,780 -197,983	-91%	-$13M	﹤0.01%	1810
2015 Q4	$24.4M	Buy	217,763 +2,362	+1%	+$236K	0.01%	735
2015 Q3	$20.7M	Buy	215,401 +108,592	+102%	+$12.4M	0.01%	757
2015 Q2	$10.9M	Buy	106,809 +791	+0.7%	+$61.4K	0.01%	939
2015 Q1	$6.58M	Buy	106,018 +4,679	+5%	+$260K	﹤0.01%	1056
2014 Q4	$4.45M	Buy	101,339 +2,445	+2%	+$112K	﹤0.01%	1161
2014 Q3	$5.6M	Buy	+98,894	New	+$4.98M	﹤0.01%	1069
2014 Q2	–	Sell	-22,623	Closed	-$1.11M	–	2858
2014 Q1	$1.11M	Buy	+22,623	New	+$1.16M	﹤0.01%	1940

Other funds holding RARE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock Group's RARE Position: Q4 2016 in Review

BlackRock Group increased its Ultragenyx Pharmaceutical (RARE) stake by 7.3% in Q4 2016, buying an estimated $122K and bringing the position to 25,325 shares worth $1.78M. The position accounts for ﹤0.01% of the portfolio, ranked #1845.

BlackRock Group first reported a position in RARE in Q1 2014 and has held it in 11 quarters since. The position peaked at $24.4M in Q4 2015. 174 funds tracked by Wall St. Rank hold RARE as of Q4 2016.

BlackRock Group held 25,325 shares of Ultragenyx Pharmaceutical worth $1.78M as of Q4 2016.
BlackRock Group bought 1,719 Ultragenyx Pharmaceutical shares in Q4 2016, an estimated $122K.
Ultragenyx Pharmaceutical made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #1845 holding.
BlackRock Group first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and has held it in 11 quarters since.
BlackRock Group's Ultragenyx Pharmaceutical position peaked at $24.4M in Q4 2015.
174 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.